5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The Human Microbiome Market is segmented by Application, Disease, Product (Probiotics, Prebiotics, Symbiotic, Other Diseases), and Geography
Fastest Growing Market:
The global human microbiome market is expected to show a CAGR of 22.60% during the forecast period. The key factors propelling the growth of this market are increasing incidence of lifestyle-related diseases and growing geriatric population.
The rising incidence of lifestyle-related diseases, globally, is a strong driver of the human microbiome market, as therapeutics may provide an alternative route to tackle significant healthcare challenges, such as obesity. The increasing occurrence of autoimmune disorders and antibiotic resistance are also important areas, which are in great need of fresh treatment approaches, and for which, microbiome therapies may have a significant impact over the next few years. With advancements in precision medicine, personalized nutrition is also playing a crucial role. Microbiome technologies strive for novel developments in the area. Cardiovascular diseases (CVD) continue to be the major cause of mortality, representing about 30% of all deaths, worldwide. Lifestyle-related diseases, like hypertension, diabetes mellitus, dyslipidaemia, and overweight/obesity, are the major risk factors for the development of CVD. With rapid economic development and increasing westernization of lifestyles in the past few decades, the prevalence of these diseases has reached alarming proportions in the recent years, which is expected to boost the growth of the human microbiome market.
The human microbiome is the aggregate of all microbiome that reside on or within human tissues and biofluids along with the corresponding anatomical sites in which they reside, including the skin, mammary glands, placenta, seminal fluid, uterus, ovarian follicles, lung, saliva, oral mucosa, conjuctiva, and gastrointestinal tract.
|Central Nervous System Disorders|
Report scope can be customized per your requirements. Click here.
The microbiome-based products for therapeutics are still in the development phase. There are a number of organizations that are developing products across various disease areas in the human microbiome space. Companies have developed their own proprietary technology platforms and innovative approaches to microbiome-based treatment. The most common strategy deployed for a variety of products is the use of natural, live bacteria, either as a single agent or in a mixture form. Some companies are engineering bacteria and are programing them to take over certain physiologic functions to tackle rare disorders.
To understand key trends, Download Sample Report
North America currently dominates the market for human microbiome due to the rising incidences of life style related diseases and autoimmune disorders in these regions. However, Asia Pacific is also expected to show a high growth rate due to improving research infrastructure in the region. In addition, several government associations are also supporting in the growth of human microbiome market in the region by providing funds and grants to increase research in the field of life science.
To understand geography trends, Download Sample Report.
The human microbiome market is less competitive and there are several players that are coming up with new products. Companies, like Yakult, DuPont, Series Therapeutics, Second Genome, and Synthetic Biologics, hold substantial shares in the market.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Lifestyle-related Diseases
4.2.2 Growing Geriatric Population
4.3 Market Restraints
4.3.1 Lack of Comprehensive Research
4.3.2 Stringent Government Regulations
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Application
5.2 By Disease
5.2.3 Autoimmune Disorder
5.2.5 Gastrointestinal Disorders
5.2.6 Central Nervous System Disorders
5.2.7 Other Diseases
5.3 By Product
5.3.4 Other Products
5.4.1 North America
18.104.22.168 United States
22.214.171.124 United Kingdom
126.96.36.199 Rest of Europe
188.8.131.52 South Korea
184.108.40.206 Rest of Asia-Pacific
5.4.4 Middle East & Africa
220.127.116.11 South Africa
18.104.22.168 Rest of Middle East & Africa
5.4.5 South America
22.214.171.124 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Enterome Bioscience
6.1.2 Yakult Honsha Co., Ltd.
6.1.4 Seres Therapeutics
6.1.5 Vithera Pharmaceuticals
6.1.6 Second Genome Inc.
6.1.7 Synthetic Biologics Inc.
6.1.8 Vedanta Biosciences Inc.
6.1.9 Osel Inc.
6.1.10 Synlogic Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments